Model Reliably Predicts Risk of Developing Psoriatic Arthritis Among Patients With Psoriasis
Investigators aimed to create and validate a risk prediction model for estimating the development of psoriatic arthritis among patients with psoriasis.
Investigators aimed to create and validate a risk prediction model for estimating the development of psoriatic arthritis among patients with psoriasis.
Investigators assessed how the outcomes of patients with psoriatic arthritis may be improved using lifestyle modifications and nonpharmacologic and psychological interventions.
Investigators analyzed the effects of biologics on pregnancy outcomes in women with psoriasis.
Investigators assessed the association between JAK inhibitors and malignancy incidence, compared with placebo, methotrexate, and TNF inhibitors.
Researchers sought to investigate the effect of targeted therapies on cardiovascular risk in psoriasis and psoriatic arthritis.
Researchers determined the effect of depression and anxiety on disease activity among patients with psoriatic arthritis.
The approval is supported by evidence from adequate and well-controlled studies of Stelara.
The PAS is supported by data from the REFLECTIONS B538-12 study, which assessed multiple switches between Abrilada and Humira, in addition to methotrexate, in adults with moderate to severe rheumatoid arthritis.
In a population-based study, researchers examined the association between psoriatic arthritis and all-cause mortality and leading causes of death.
Researchers studied the immune response to COVID-19 vaccination in patients with psoriatic arthritis receiving treatment with tumor necrosis factor inhibitors.